Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 2,102 | $430.72 | $905,367.55 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,520 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $430.42 to a high of $431.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 2,725 | $429.93 | $1,171,571.79 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,622 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $429.39 to a high of $430.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2020 Filed Dec 11, 2020 22:00 UTC Amendment |
AYERS JONATHAN WDirector
|
Tax withholdingCommon Stock | 26,120 | $424.82 | $11,096,298.40 |
DisclosureSEC source: 0001567619-20-020982 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,347 F1 · shares: Shares withheld for the payment of taxes on the conversion of 14,791 deferred stock units ('DSUs') acquired pursuant to the IDEXX Laboratories, Inc. Executive Deferred Compensation Plan and which were reported previously on Table I and represented a right to receive one share of Issuer common stock without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on November 7, 2007 and on June 15, 2015 (the "Stock Splits"). The total number of securities previously reported as beneficially owned, as adjusted to reflect the Stock Splits, is 59,164 DSUs, which were converted to an equal number of shares of Issuer common stock one year following the reporting person's resignation as an executive from IDEXX Laboratories, Inc. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 22:01 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 15 | $424.82 | $6,372.30 |
DisclosureSEC source: 0001567619-20-018549 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,862 F1 · shares: 1. Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 22:01 UTC |
ESSIG STUARTDirector
|
GrantCommon Stock | 47 | $424.82 | $19,966.54 |
DisclosureSEC source: 0001567619-20-018548 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · derivative · entry 7 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,028 Underlying: Common Stock · 6,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 22,028 shares of IDEXX Laboratories, Inc. common stock that vests in five annual installments beginning February 14, 2017. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,316 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · derivative · entry 6 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,316 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 9,677 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 1,285 | $389.08 | $499,965.10 |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · nonDerivative · entry 5 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,906 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $389.02 to a high of $389.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 2,788 | $388.79 | $1,083,951.54 |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · nonDerivative · entry 4 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,191 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $388.01 to a high of $389.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 3,243 | $387.33 | $1,256,103.41 |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · nonDerivative · entry 3 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $387.00 to a high of $387.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 6,000 | $67.85 | $407,100.00 |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · nonDerivative · entry 2 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:00 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 1,316 | $79.54 | $104,674.64 |
DisclosureSEC source: 0001567619-20-016342 · doc1.xml · nonDerivative · entry 1 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 9,682 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · derivative · entry 7 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,316 Underlying: Common Stock · 9,682 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 9,677 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 9,682 | $384.11 | $3,718,989.81 |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · nonDerivative · entry 5 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,906 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $384.00 to a high of $384.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 9,682 | $79.54 | $770,106.28 |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · nonDerivative · entry 4 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,356 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · derivative · entry 6 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,998 Underlying: Common Stock · 8,356 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 9,677 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 400 | $389.06 | $155,624.00 |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · nonDerivative · entry 3 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,906 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
SaleCommon Stock | 7,956 | $388.57 | $3,091,495.54 |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · nonDerivative · entry 2 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,306 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $388.03 to a high of $388.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:18 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 8,356 | $79.54 | $664,636.24 |
DisclosureSEC source: 0001567619-20-016171 · doc1.xml · nonDerivative · entry 1 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14 shares purchased under the Issuer's Employee Stock Purchase Plan on June 30, 2020. Read SEC document |
| August 25, 2020 Filed Aug 28, 2020 21:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,467 Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 21:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,722 | Not disclosed Strike: $63.95 | Not disclosed |
DisclosureSEC source: 0001567619-20-015869 · doc1.xml · derivative · entry 3 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,722 shares Expires 2025-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 21:00 UTC |
JUNIUS DANIEL MDirector
|
SaleCommon Stock | 3,722 | $382.61 | $1,424,063.25 |
DisclosureSEC source: 0001567619-20-015869 · doc1.xml · nonDerivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,847 Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 21:00 UTC |
JUNIUS DANIEL MDirector
|
Exercise / conversionCommon Stock | 3,722 | $63.95 | $238,021.90 |
DisclosureSEC source: 0001567619-20-015869 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,954 Underlying: Common Stock · 18,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 500 | $384.57 | $192,285.00 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 2,634 | $383.78 | $1,010,865.19 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,967 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $383.479 to a high of $383.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 7,023 | $382.74 | $2,687,977.40 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,601 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $382.47 to a high of $383.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 7,445 | $382.08 | $2,844,610.91 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,624 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $381.45 to a high of $382.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 398 | $380.41 | $151,403.54 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,069 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $380.24 to a high of $380.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 21:05 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionCommon Stock | 18,000 | $67.85 | $1,221,300.00 |
DisclosureSEC source: 0001567619-20-015900 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 21:01 UTC |
Underberg Sharon E.CVP, Gen. Counsel & Secretary
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0001567619-20-015833 · doc1.xml · derivative · entry 2 Underberg Sharon E. · CIK 0001630353 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 21:01 UTC |
Underberg Sharon E.CVP, Gen. Counsel & Secretary
|
Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0001567619-20-015833 · doc1.xml · nonDerivative · entry 1 Underberg Sharon E. · CIK 0001630353 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,107 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · derivative · entry 7 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769 Underlying: Common Stock · 1,107 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 1,906 shares of Issuer common stock that vests as to 1 share on February 14, 2017, 29 shares on February 14, 2018, 365 shares on February 14, 2019, 742 shares on February 14, 2020 and as to the remainder on February 14, 2021. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 698 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · derivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 698 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 1,366 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionCommon Stock | 1,107 | $67.85 | $75,109.95 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionCommon Stock | 698 | $79.54 | $55,518.92 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC |
Claflin Bruce L.Director
|
SaleCommon Stock | 5,629 | $385.11 | $2,167,802.77 |
DisclosureSEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 3 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $384.90 to a high of $385.765 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-015832 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that vested on February 14, 2020. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,880 | Not disclosed Strike: $53.19 | Not disclosed |
DisclosureSEC source: 0001567619-20-015832 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,880 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 4,700 shares of Issuer common stock that vested in five annual installments beginning on January 1, 2015. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split"). Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0001567619-20-015832 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:01 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 1,880 | $53.19 | $99,987.80 |
DisclosureSEC source: 0001567619-20-015832 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 20,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,954 Underlying: Common Stock · 20,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 100 | $386.40 | $38,640.00 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,467 Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 7,383 | $385.60 | $2,846,901.78 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,567 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $385.39 to a high of 386.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 4,477 | $384.94 | $1,723,394.29 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,950 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $384.38 to a high of $385.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 4,461 | $383.81 | $1,712,174.63 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,487 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $383.22 to a high of $384.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
SaleCommon Stock | 3,579 | $382.28 | $1,368,184.06 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,888 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $382.11 to a high of $382.961 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 21:00 UTC |
AYERS JONATHAN WDirector
|
Exercise / conversionCommon Stock | 20,000 | $67.85 | $1,357,000.00 |
DisclosureSEC source: 0001567619-20-015831 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 28, 2020 21:01 UTC |
AYERS JONATHAN WDirector
|
GiftCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016146 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,467 Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:09 UTC |
Claflin Bruce L.Director
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,629 | Not disclosed Strike: $70.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-015709 · doc1.xml · derivative · entry 4 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,629 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2016 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.